ipilimumab + nivolumab + pegylated liposomal doxorubicin + cyclophosphamide

This combination therapy, evaluated in the ICON clinical trial (NCT03409198) sponsored by Oslo University Hospital, consists of the immune checkpoint inhibitors ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) administered alongside immunogenic chemotherapy, which includes pegylated liposomal doxorubicin and low-dose cyclophosphamide. The regimen is specifically investigated for the treatment of metastatic hormone receptor-positive (HR+) breast cancer. The therapeutic rationale is to utilize chemotherapy to induce immunogenic cell death, thereby releasing tumor antigens and enhancing the efficacy of the dual checkpoint blockade in a patient population where immunotherapy has traditionally shown limited activity. Bristol Myers Squibb provided the checkpoint inhibitors and funding support for this randomized Phase IIb study.

Other names

ICON regimenipilimumab and nivolumab with immunogenic chemotherapy